Neurological disordersLario Therapeutics wins $2.4m grants to advance calcium channel drugs for Parkinson’s and PTSDEdinburgh-based Lario Therapeutics has received $2.4 million (approximately €2m) in grant funding from The Michael J. Fox Foundation and Wellcome to expand its drug discovery platform targeting voltage-gated … more ➔
adobe.stock.com - ipopbaAlzheimerJ&J stops enrollment in an AC Immune-partnered Alzheimer trial, but the reason is not yet clearA pause in the collaborative Alzheimer trial of Johnson & Johnson and partner AC Immune from Switzerland raises some questions. Whether the pause has something to do with overall recruting difficulties … more ➔
COPDForbion and Sanofi drive $75M investment in COPD biotech AltesaForbion has led a $75 million investment in Altesa BioSciences, positioning the biotech to run a phase IIb trial in chronic obstructive pulmonary disease (COPD) patients in the second quarter. more ➔
Unsplash+Drug discoveryNovartis expands cardiovascular pipeline with $1.8bn macrocycle agreement with Unnatural ProductsCalifornia-based Unnatural Products, Inc. (UNP) has signed a research collaboration and licensing agreement with Basel-based multinational pharmaceutical company Novartis to develop macrocyclic peptide … more ➔
NeurologyPLL Therapeutics reports positive phase I/II data for gut-targeting ALS therapyThe French biopharmaceutical company, PLL Therapeutics, announced positive results from a phase I/II clinical trial for its investigational therapy PLL001 to treat amyotrophic lateral sclerosis (ALS), … more ➔
Unsplash+OphthalmologyAxol buys Newcells’ ophthalmology business to grow drug discovery portfolioAxol Bioscience has acquired Newcells Biotech’s ophthalmology business to expand its portfolio of drug discovery and safety testing models. more ➔
BoehringerBoehringer drops inhaled gene therapy for cystic fibrosisSetback for Boehringer Ingelheim: the company has halted development of its inhaled gene therapy BI 3720931 for cystic fibrosis after a phase 1/2 trial failed to deliver efficacy data supporting further … more ➔
Bayer AGBayerUS settlement: Has Bayer untied the Monsanto knot?Years of uncertainty surrounding the numerous pending lawsuits against Bayer’s Monsanto unit could now be brought to an end through a costly but capped court settlement. Under the proposed agreement, … more ➔
depressionCompass Pathways clears second phase III hurdle for psilocybin in treatment-resistant depressionThe share price of London-based Compass Pathways soared over 30% on Tuesday after the company reported that its synthetic psilocybin formulation COMP360 had met the primary endpoint in the second of … more ➔
Unsplash+fundingCubaseBio secures €5.9m to scale 3D spatial transcriptomicsSwedish startup CubaseBio has raised €5.9 million in blended financing to advance its next-generation 3D spatial transcriptomic technology. Of that total, €3.9 million comes from private capital. … more ➔
adobe.stock.com - ipopba
Unsplash+
Unsplash+
Bayer AG
Unsplash+